logo
Plus   Neg
Share
Email

Teva Commences Launch Of Irbesartan And Irbesartan-hydrochlorothiazide Tablets

Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA) Monday said it has commenced commercial launch of both irbesartan and irbesartan-hydrochlorothiazide tablets, the company's generic versions of Sanofi Aventis' high blood pressure treatments, Avapro and Avalide tablets.

The brand products had annual sales of around $464 million and $124 million, respectively, in the U.S., based on IMS sales data.

As the first company to file Abbreviated New Drug Applications containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported that its first-quarter comparable earnings per share from continuing operations grew 8% year-over-year to $0.47. On average, 20 analysts polled by Thomson Reuters expected the company to report profit per share of $0.46 for the quarter. Analysts' estimates typically... Eli Lilly and Co. (LLY) Tuesday reported a profit for its first-quarter, compared to a loss last year, primarily driven by higher operating income. Quarterly revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products. The company raised its 2018 outlook. Both adjusted earnings per share and revenue for the quarter beat analysts' expectations. Shares of SAP SE were gaining around 3 percent in German trading after the software giant reported Tuesday higher first-quarter profit with strong growth in cloud subscriptions and support revenues. The company further lifted its outlook for fiscal 2018. CEO said, "With an increasing share of predictable revenues, our beyond expectations profitability is cause for even greater shareholder confiden
Follow RTT